These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment. Wagner L; Björkqvist M; Lundh SH; Wolf R; Börgel A; Schlenzig D; Ludwig HH; Rahfeld JU; Leavitt B; Demuth HU; Petersén Å; von Hörsten S J Neurochem; 2016 Jun; 137(5):820-37. PubMed ID: 27016395 [TBL] [Abstract][Full Text] [Related]
9. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years. Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511 [TBL] [Abstract][Full Text] [Related]
10. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease. Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403 [TBL] [Abstract][Full Text] [Related]
12. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. Ou ZA; Byrne LM; Rodrigues FB; Tortelli R; Johnson EB; Foiani MS; Arridge M; De Vita E; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ Sci Rep; 2021 Feb; 11(1):3481. PubMed ID: 33568689 [TBL] [Abstract][Full Text] [Related]
13. Investigating the Transition of Pre-Symptomatic to Symptomatic Huntington's Disease Status Based on Omics Data. Christodoulou CC; Zachariou M; Tomazou M; Karatzas E; Demetriou CA; Zamba-Papanicolaou E; Spyrou GM Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049985 [TBL] [Abstract][Full Text] [Related]
14. Regional subcortical shape analysis in premanifest Huntington's disease. Tang X; Ross CA; Johnson H; Paulsen JS; Younes L; Albin RL; Ratnanather JT; Miller MI Hum Brain Mapp; 2019 Apr; 40(5):1419-1433. PubMed ID: 30376191 [TBL] [Abstract][Full Text] [Related]
15. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR; Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844 [TBL] [Abstract][Full Text] [Related]
16. Early grey matter changes in structural covariance networks in Huntington's disease. Coppen EM; van der Grond J; Hafkemeijer A; Rombouts SA; Roos RA Neuroimage Clin; 2016; 12():806-814. PubMed ID: 27830113 [TBL] [Abstract][Full Text] [Related]
17. Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington's disease. van de Zande NA; Bulk M; Najac C; van der Weerd L; de Bresser J; Lewerenz J; Ronen I; de Bot ST Neuroimage Clin; 2023; 39():103450. PubMed ID: 37327706 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. Byrne LM; Rodrigues FB; Johnson EB; De Vita E; Blennow K; Scahill R; Zetterberg H; Heslegrave A; Wild EJ Sci Rep; 2018 Mar; 8(1):4260. PubMed ID: 29523800 [TBL] [Abstract][Full Text] [Related]